CD8A and type 1 diabetes mellitus: In a recent phase I clinical trial, low dose IL-2 bolstered polyclonal Treg engraftment in patients with T1D but also, imparted undesirable off-target expansion of cytotoxic cell subsets, such as activated natural killer (NK), mucosal associated invariant T (MAIT), and CD8+ T cells (15).